Comparative Pharmacology
Head-to-head clinical analysis: CALDEROL versus DRISDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALDEROL versus DRISDOL.
CALDEROL vs DRISDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vitamin D analog; binds to vitamin D receptors, increasing calcium absorption in intestines and promoting bone mineralization.
Drisdol (ergocalciferol) is a vitamin D2 analog that increases intestinal absorption of calcium and phosphate, promotes renal tubular reabsorption of calcium, and stimulates bone mineralization by binding to vitamin D receptors, which regulate gene expression.
Oral: 0.25-0.5 mcg once daily; titration up to 1 mcg daily based on serum calcium levels. Intravenous: 0.5-2 mcg bolus; maintenance 0.5-2 mcg daily.
50,000 IU orally once weekly for 8 weeks, then 50,000 IU orally once monthly for maintenance.
None Documented
None Documented
Terminal elimination half-life is approximately 20-30 hours; clinically, steady-state is achieved within 5-7 days.
Terminal elimination half-life is approximately 19–48 hours after a single oral dose, with clinical context: repetitive dosing increases half-life due to accumulation in adipose tissue, leading to a functional half-life of weeks to months for vitamin D stores.
Primarily fecal (biliary) as unchanged drug and metabolites (approx. 80%); renal excretion accounts for less than 20%.
Primarily excreted via bile into feces (~90%), with renal excretion accounting for the remainder (~10%). Biliary excretion of metabolites is the major route, with enterohepatic recycling contributing to prolonged elimination.
Category C
Category C
Vitamin D Analog
Vitamin D Analog